SUPPORTING INFECTIOUS DISEASE RESEARCH

Plasmodium falciparum, Strain 3D7

Catalog No. MRA-102

This reagent is the tangible property of the U.S. Government.

Product Description: *Plasmodium falciparum (P. falciparum)*, strain 3D7 was cloned from the NF54 strain by limiting dilution; it is reported as a pyrimethamine-sensitive strain. The parent NF54 strain was isolated from a patient from the Netherlands who had never left the country.

Lot¹: 64202795

Manufacturing Date: 14MAY2016

SPECIFICATIONS	RESULTS
Blood-stage parasites present	Blood-stage parasites present
-	
Report results	8.4 ± 0.6 nM
	8.8 ± 0.4 nM
	92.7 ± 8.6 nM
	8.0 ± 0.6 nM
	39.0 ± 2.7 nM
Report results	371800 ± 77602 nM
	99.7% sequence identity to
	P. falciparum, strain 3D7
(GenBank: LN999943.1)	(GenBank: LN999943.1)
	(Figure 1)
~ 600 to 900 base pair amplicon	~ 900 base pair amplicon
Report results	3.05%
≥ 2%	4.83%
Report results	1.09%
≥ 1%	2.84%
Growth in infected red blood cells	Growth in infected red blood cells
No growth	No growth
	No growth
No growth	No growth
None detected	None detected
	Blood-stage parasites present Report results Pop% sequence identity to P. falciparum, strain 3D7 (GenBank: LN999943.1) ~ 600 to 900 base pair amplicon Report results ≥ 2% Report results ≥ 1% Growth in infected red blood cells No growth No growth

¹MRA-102 was produced by cultivation of BEI Resources MR-MRA-102 lot 63085271 in fresh human erythrocytes suspended in RPMI 1640 medium, adjusted to contain 10% (v/v) heat-inactivated human serum (pooled Type A), 25 mM HEPES, 2 mM L-glutamine, 4 g/L D-glucose, 0.005 µg/mL hypoxanthine and 2.5 µg/mL gentamicin. The culture was incubated at 37°C in sealed flasks outgassed with blood-gas atmosphere (90% N₂,

BEI Resources www.beiresources.org E-mail: <u>contact@beiresources.org</u> Tel: 800-359-7370 Fax: 703-365-2898 DICI RESOURCES

SUPPORTING INFECTIOUS DISEASE RESEARCH

5% CO₂, 5% O₂) and monitored for parasitemia daily for 17 days. Every 1 to 3 days, uninfected, leukocyte filtered, Type O erythrocytes in complete culture medium were added dropwise to the culture as needed and monitored for hematocrit.

²Testing completed on vialed post-freeze material.

³Blood-stage malaria parasites (rings, trophozoites, schizonts +/- gametocytes) were examined by microscopic Giemsa-stained blood smears of an *in vitro* human blood culture over 14 days.

⁴A SYBR Green I[®] anti-malarial drug sensitivity assay in 96-well plates was used to determine IC₅₀ values of an active (> 70% ring stage) parasite culture in the presence of each antimalarial drug [Hartwig, C. L., et al. "XI: I. SYBR Green I[®]-Based Parasite Growth Inhibition Assay for Measurement of Antimalarial Drug Susceptibility in *Plasmodium falciparum*." In <u>Methods in Malaria Research Sixth Edition</u>. (2013) Moll, K., et al. (Ed.), EVIMalaR, pp. 122-129. Available at: <u>https://www.beiresources.org/Publications/MethodsinMalariaResearch.aspx</u>].

⁵The high-dilution results are shown, as the low-dilution results were not interpretable for this lot.

⁶Primer sequences and conditions for PCR are available upon request.

⁷Testing completed on bulk material prior to vialing and freezing.

⁸Parasitemia was determined after 17 days post infection by microscopic counts of Giemsa-stained blood smears.

⁹Post-freeze parasitemia was determined after 4 days post infection by microscopic counts of Giemsa-stained blood smears.

¹⁰Viability was confirmed by examination of infected erythrocytes for parasitemia at 4 days post infection.

¹¹Atlas, Ronald M. <u>Handbook of Microbiological Media</u>. 3rd ed. Ed. Lawrence C. Parks. Boca Raton: CRC Press, 2004, p. 798.

Figure 1: MRA-102 MSP2 Sequence

AGGTAATTAA AACATTGTCT ATTATAAATT TCTTTTATTT TTGTTACCTT TAATATTAAA AATGAAAGTA AATATAGCAA CACATTCATA AACAATGCTT ATAATATGAG TATAAGGAGA AGTATGGCAG AAAGTAAGCC TTCTACTGGT GCTGGTGGTA GTGCTGGTGG TAGTGCTGGT GGTAGTGCT GTGGTAGTGC TGGTGGTAGT GCTGGTGGTA GTGCTGGTC TGGTGATGGT AATGGTGCAG ATGCTGAGGG AAGTTCAAGT ACTCCCGCTA CTACCACAC TACCAAAACT ACCACAACTA CCACAACTA TAATGATGCA GAAGCATCTA CCAGTACCTC TTCAGAAAAT CCAAATCAA AAAATGCCGA AACAAATCCA AAAGGTAAAG GAGAAGTTCA AGAACCAAAT CAAGCAAATA AAGAAACTCA AAATAACTCA AATGTTCAAC AAGAACTCCA AACTAAATCA AATGTTCCAC CCACTCAAGA TGCAGACACT AAAAGTCCTA CTGCACAACC TGAACAAGCT GAAAATTCTG CTCCAACAGC CGAACAAACT GAATCCCCG AATTACAATC TGCACCAGAG AATAAAGGTA CAGGACAACA TGGACATATG CATGGTTCTA GAAATAATCA TCCACAAAAT ACTTCTGATA GTCAAAAAGA ATGTACCGAT GGTAACAAG AAAACTGTGG AGCAGCAACA TCCCTCTTAA ATAACTCTAG TAATATTGCT TCAATAAATA AATTGTTGT TTTAATTTCA GCAAACACT GTTTTATCTT TTGCCATATT CATATA

/Heather Couch/

Heather Couch

Program Manager or designee, ATCC Federal Solutions

ATCC[®], on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC[®]'s knowledge.

ATCC[®] is a trademark of the American Type Culture Collection. You are authorized to use this product for research use only. It is not intended for human use.



16 NOV 2018